SCHEMBL4723949

SCHEMBL4723949

CCCN(CCC)N1CCOCC1

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.32
POLB P06746 2/20 0.32
HTT P42858 2/20 0.32
TSHR P16473 1/20 0.32
LMNA P02545 2/20 0.32
MEN1 O00255 1/20 0.31
GAA P10253 1/20 0.31
KMT2A Q03164 1/20 0.31
MAPK1 P28482 2/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP1A2 P05177 1/20 0.31
CHRM2 P08172 1/20 0.31
CHRM1 P11229 1/20 0.31
HTR2A P28223 1/20 0.31
SCN1A P35498 1/20 0.31
HTR2B P41595 1/20 0.31
KCNH2 Q12809 1/20 0.31
SCN2A Q99250 1/20 0.31
SIGMAR1 Q99720 1/20 0.31
SCN3A Q9NY46 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4719759 0.93 SMN1; SMN2 (0.35) SMN1; SMN2POLBHTTTSHRLMNA
SCHEMBL4721519 0.92 LMNA (0.35) SMN1; SMN2POLBHTTLMNAMEN1
SCHEMBL11126884 0.86
SCHEMBL4720873 0.86 LMNA (0.37) SMN1; SMN2POLBHTTTSHRLMNA
SCHEMBL4763981 0.82 SMN1; SMN2 (0.39) SMN1; SMN2POLBHTTTSHRMEN1
Hydrochloric Acid SCHEMBL28309131 0.81 DNM1 (0.40) SMN1; SMN2POLBHTTTSHRLMNA
Bromide SCHEMBL28309885 0.81 DNM1 (0.40) SMN1; SMN2POLBHTTTSHRLMNA
Bromide SCHEMBL28875153 0.81 DNM1 (0.40) SMN1; SMN2POLBHTTTSHRLMNA
Hydrochloric Acid SCHEMBL28309112 0.81 DNM1 (0.40) SMN1; SMN2POLBHTTTSHRLMNA
Hydrochloric Acid SCHEMBL28309047 0.81 DNM1 (0.40) SMN1; SMN2POLBHTTTSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2888255-B1 HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE UNIV TEXAS (US) 2018-07-18 EP disclosed
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 SMN1; SMN2 4511/4885POLB 2602/4885HTT 2486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.